Published in
American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 4(65), 2021
DOI: 10.1128/aac.01618-20
Links
Tools
Comparative pharmacodynamics of echinocandins against Aspergillus fumigatus using an in vitro pharmacokinetic/pharmacodynamic model that correlates with clinical response to caspofungin therapy: Is there a place for dose optimization?
Journal article published in 2021 by
Maria Siopi 
,
David S. Perlin,
Maiken C. Arendrup ,
Spyros Pournaras,
Joseph Meletiadis
,
David S. Perlin,
Maiken C. Arendrup ,
Spyros Pournaras,
Joseph Meletiadis
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Data provided by 
Abstract
Echinocandins have been used as primary therapy of invasive aspergillosis (IA), with suboptimal results at standard dosing. Here, we explored the efficacy of dose escalation in a validated in vitro pharmacokinetic/pharmacodynamic (PK/PD) model.